Affordable Access

Publisher Website

Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.

  • Chuntova, Pavlina1
  • Chow, Frances2
  • Watchmaker, Payal B1
  • Galvez, Mildred3
  • Heimberger, Amy B4
  • Newell, Evan W5
  • Diaz, Aaron1
  • DePinho, Ronald A6
  • Li, Ming O7
  • Wherry, E John8
  • Mitchell, Duane9
  • Terabe, Masaki10
  • Wainwright, Derek A11
  • Berzofsky, Jay A10
  • Herold-Mende, Christel12
  • Heath, James R13
  • Lim, Michael14
  • Margolin, Kim A15
  • Chiocca, E Antonio16
  • Kasahara, Noriyuki1
  • And 15 more
  • 1 Department of Neurological Surgery, UCSF, San Francisco, California.
  • 2 Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • 3 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, California.
  • 4 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 5 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 6 Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 7 Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 8 Department of Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  • 9 Department of Neurosurgery, University of Florida College of Medicine, Gainesville, Florida.
  • 10 Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • 11 Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • 12 Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany. , (Germany)
  • 13 Institute for Systems Biology, Seattle, Washington.
  • 14 Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • 15 Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
  • 16 Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • 17 Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • 18 Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California.
  • 19 Department of Microbiology, Immunology & Molecular Genetics, UCLA, Los Angeles, California.
  • 20 Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina.
  • 21 Department of Medicine/Medical Oncology, Harvard Medical School, Boston, Massachusetts.
  • 22 Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri.
  • 23 Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • 24 Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany. , (Germany)
  • 25 Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
  • 26 Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • 27 Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • 28 Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany. , (Germany)
  • 29 DKTK CCU Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. , (Germany)
Published Article
Oxford University Press
Publication Date
Mar 25, 2021
DOI: 10.1093/neuonc/noaa277
PMID: 33367885


Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner. © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]

Report this publication


Seen <100 times